Abstract
Background and purpose: COVID-19 is a novel infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in which neurological complications have been increasingly recognized. Acute symptomatic epileptic seizures and status epilepticus are frequently reported neurological complications associated with this infection. The nervous system damage caused by SARS-CoV-2 may be mediated by the immune system. Interleukin 6 (IL-6), an important component of the cytokine storm, is directly correlated with the severity of symptoms. Tocilizumab is an inhibitor of IL-6 receptors, which blocks IL-6-mediated signal transduction and is used in the treatment of COVID-19 and status epilepticus.
Case report: A patient with the Unverricht-Lundborg disease is presented who had developed refractory recurrent status epilepticus during COVID-19 infection, which was finally controlled by treatment with tocilizumab.
Discussion: Tocilizumab, an IL-6 inhibitor, may be considered as a treatment option in patients with status epilepticus and refractory seizures.
Keywords: COVID-19 infection; Unverricht-Lundborg disease; status epilepticus; tocilizumab.
【저자키워드】 tocilizumab., COVID-19 infection, status epilepticus, Unverricht-Lundborg disease, 【초록키워드】 COVID-19, Treatment, SARS-CoV-2, coronavirus, Tocilizumab, IL-6, Infection, Infectious disease, immune system, interleukin 6, symptomatic, Patient, nervous system, receptors, disease, Signal transduction, IL-6 inhibitor, Seizure, Neurological complication, Seizures, acute respiratory syndrome, severity of symptoms, inhibitor of IL-6, block, caused, reported, correlated, increasingly, the cytokine storm, treatment with tocilizumab, 【제목키워드】 Tocilizumab,